SEC Tracker
Get the app

Edgewise Therapeutics EWTX

Jonathan C Fox CEO John Doe purchased 10,000 shares of EWTX stock for $200,000, signaling strong insider confidence in the company's outlook. This sizable open-market purchase by a key executive suggests a bullish sentiment and positive expectations for Edgewise's future performance.

Jonathan C Fox, insider filing for EWTX

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Edgewise Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Innoviva INVA public float $1.3B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  4. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  5. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.